Company profile
Isracann Biosciences Inc.
OTC: ISCNF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 22
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ market scale, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.7M
Employees
—
as of 2026-08-31
Market cap
$176
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2022
Net income-$3.7M-4.7M CAD2022
Operating income-$1.9M-2.4M CAD2022
Total assets$3.2M4.1M CAD2022
Liabilities$3.0M3.8M CAD2022
Equity$232.2k293.7k CAD2022
Revenue trend
FY2017 – FY2022 · USD
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Isracann Biosciences Inc.’s revenue?
Isracann Biosciences Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Cotinga Pharmaceuticals Inc.——ForU Holdings, Inc.——Dermisonics, Inc.——Legacy Technology Holdings, Inc.——Pure Global Cannabis Inc.——Aamaxan Transport Group, Inc.——Key facts
CEOAjay Singh Kaila
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: ISCNF
Employees—
IPO date2017-12-15
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.